Kauppila A, Rönnberg L
Obstet Gynecol. 1985 Mar;65(3):379-83.
Twenty patients with moderate to very severe painful menstrual periods secondary to endometriosis were treated in a double-blind, four-period, crossover clinical trial with naproxen sodium and placebo. Complete or substantial pain relief was obtained in 83% of the cases of painful menstruation with naproxen sodium and in 41% with placebo (P = .008). Only 5% of the naproxen sodium-treated women needed supplemental analgesics compared with 36% of the placebo-treated women (P = .002). There was a trend towards diminished interference of dysmenorrhea with normal patient activities during naproxen sodium treatment compared with placebo (P = .069). No significant side effects occurred with either treatment. These results indicated that naproxen sodium is efficacious and safe for the treatment of menstrual distress in patients with endometriosis.
20名因子宫内膜异位症导致中度至非常严重痛经的患者,在一项双盲、四阶段交叉临床试验中接受了萘普生钠和安慰剂治疗。使用萘普生钠治疗的痛经患者中,83%获得了完全或显著的疼痛缓解,而使用安慰剂的这一比例为41%(P = 0.008)。与36%使用安慰剂治疗的女性相比,仅5%使用萘普生钠治疗的女性需要补充镇痛药(P = 0.002)。与安慰剂相比,在萘普生钠治疗期间痛经对患者正常活动的干扰有减少趋势(P = 0.069)。两种治疗均未出现显著副作用。这些结果表明,萘普生钠治疗子宫内膜异位症患者的经期疼痛有效且安全。